Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06177860
Other study ID # 00982023
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 17, 2023
Est. completion date November 30, 2024

Study information

Verified date January 2024
Source Hospital El Cruce
Contact Maximiliano de Abreu, PhD
Phone 5491156577631
Email maxideabreu@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cocaine use has increased in our country in recent decades. It is associated with cardiovascular events and early atherosclerotic disease. Acute coronary syndrome (ACS) is one of its most frequent and serious manifestations. There is a lack of scientific information on ACS associated with acute and chronic cocaine use in Argentina. This study aims to describe the socioeconomic, clinical, and coronary angiographic characteristics, as well as the extent of atherosclerotic disease in patients with ACS associated with cocaine use, and to compare them with ACS not associated with cocaine use. Methods: We propose an observational, analytical, single-center, two-phase study, with a retrospective and a prospective component. Patients with a diagnosis of ACS admitted to the coronary care unit of a high-complexity public hospital will be included. Clinical, biochemical, coronary angiographic, extracoronary atherosclerotic disease extension and prognostic variables will be described. These variables will be compared between patients with cocaine-associated ACS and non-cocaine-associated ACS.


Description:

General objective: - To identify socioeconomic, clinical, electrocardiographic, coronary angiographic, and atherosclerotic disease extent differences between ACS patients with a history of cocaine use and those without cocaine use. Specific objectives: To characterize and compare between both groups: - Clinical characteristics. - Coronary angiographic findings - Extent of myocardial damage related and unrelated to ACS. - Severe complications during hospitalization (mortality, resuscitated cardiac arrest, arrhythmias, use of IV inotropics and mechanical ventilatory support). - Extent of noncoronary vascular disease. Design: A quantitative approach will be used, with an observational, analytical, single-center, two-stage design. In the retrospective stage, cases admitted from April 2019 to June 2023 for ACS will be included, based on data collected in the routine practice of the coronary care unit. In the prospective stage, all cases admitted to our institution for ACS from November 1, 2023, to November 2024 will be included. Inclusion criteria: - Age ≥18 years. - Hospitalization with a diagnosis of ACS. For the prospective stage, acceptance to participate in the study and informed consent will be added. Exclusion criteria: Retrospective stage: patients who were not questioned about cocaine use. Prospective stage: patients who could not be interviewed to determine their history of cocaine use because of their clinical condition. Procedures: Two groups will be defined according to the history of cocaine use: cocaine-associated ACS and non-cocaine-associated ACS. For the retrospective phase, all patients admitted to the coronary unit for ACS in the period established for the study will be reviewed. It is standard practice to ask about cardiovascular risk factors, history of substance use, including cocaine, and other clinical history. We expect to correctly identify cases of ACS associated and not associated with cocaine use. In all cases included in both stages, the clinical, electrocardiographic, biochemical, and coronary angiographic characteristics and the extent of extra coronary atherosclerotic disease, complications, and prognosis will be described and compared between the two groups. In the prospective phase of the study, where medically necessary, cardiac magnetic resonance imaging (MRI) will be performed to assess the extent of ACS-related and non-ACS-related myocardial necrosis and edema. Cardiac MRI findings will be compared between groups. Clinical follow-up will be limited to hospitalization. Main study variables and measurement instruments: - ACS associated with cocaine and other substance use: They will be revealed by questioning, following evidence-based recommendations. ACS associated with cocaine use will be considered for those patients who verbally report the history. - Clinical variables: Will be recorded on admission: age, weight and height, blood pressure, heart rate, cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking), use of other substances (marijuana, using the same criteria as for cocaine), cardiovascular history (myocardial infarction, stroke, coronary revascularization, peripheral vascular disease, and heart failure). - Electrocardiographic variables: 12-lead electrocardiograms will be performed on admission and during hospitalization to classify ACS as ST-elevation myocardial infarction (STEMI) or non-ST-elevation acute coronary syndrome (NSTEMI), to describe the location of ACS and to detect complications. - Biochemical: a general and specific biochemical evaluation of ACS (CPK, CK mb, troponin, Pro BNP) will be performed. Peak enzymatic elevation of CPK and troponins will be used as a biochemical indicator of the extent of myocardial necrosis. - Echocardiography: an assessment of ventricular function will be performed by measuring ejection fraction, diastolic dysfunction, and wall motility disorders. The presence of mechanical complications will be evaluated by this method. - Extent and complexity of coronary atherosclerotic disease: coronary angiography will be used to define the extent and complexity of coronary lesions using the SYNTAX score. Also, an assessment of acute pathophysiological mechanisms related to ACS (thrombus, spasm, coronary dissection, as dichotomous variables: present or absent) will be performed. - Extent of extra coronary atherosclerotic disease: ankle-brachial index (ABI) will be used as an indicator of peripheral vascular disease of the lower limbs. The presence, morphology, and extent of atherosclerotic plaque at the carotid level will be determined by carotid Doppler ultrasound. - MRI: the degree of myocardial necrosis and edema related and unrelated to ACS will be assessed, as a manifestation of acute and chronic myocardial damage associated with ACS and cocaine use. Statistical analysis: Continuous variables will be described as mean and standard deviation in the case of normal distribution or median and interquartile range, and categorical variables will be described as numbers and percentages. Differences between groups for continuous variables will be evaluated with the T-test for variables with a normal distribution, and the Kruskal-Wallis test for nonparametric variables. Categorical variables will be compared using the chi-squared test and Fisher's exact test. Multiple logistic regression models will be developed to determine the independent association between cocaine use and the dependent variables of interest. Statistical analysis will be performed with the R Studio program. Procedures to ensure the ethical aspects of the research: All study procedures will be conducted following international ethical norms and standards to respect participant's rights and protect confidentiality. In addition, all study procedures conform to the principles of the Declaration of Helsinki and CIOMS guidelines. The research protocol was submitted for evaluation and approved by the Research Ethics Committee (REC) of the El Cruce Hospital. For the retrospective stage, the research team will make every effort to contact patients who meet the inclusion criteria to request informed consent for their data to be analyzed, undertaking to guarantee the anonymity of personal data. For the prospective stage of the study, potentially eligible individuals will receive a detailed explanation of the objectives and procedures before enrollment. They will be asked to sign the informed consent form (ICF). Participation is voluntary and anonymity and confidentiality of information are compromised. At this stage, only cases that have signed the ICF will be included. All information related to the study will be securely archived with access codes only available to the research team. Personal identification records will be kept separately from study records identified by code number. Data collection forms will be coded to maintain participant confidentiality. The local database will be protected with a password-protected access system. Study key codes linking participant identification numbers to other identifying information will be stored in a separate, locked file in a limited access area.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date November 30, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 - Hospitalization due to diagnosis of ACS, made by the treating medical team. For the prospective stage, it will be added: - Acceptance to participate in the study and willingness to sign the informed consent. Exclusion Criteria: - Patients who, due to their clinical condition, cannot be interviewed to determine their history of cocaine use.

Study Design


Locations

Country Name City State
Argentina Hospital El Cruce Florencio Varela Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
Hospital El Cruce

Country where clinical trial is conducted

Argentina, 

References & Publications (8)

Aquaro GD, Gabutti A, Meini M, Prontera C, Pasanisi E, Passino C, Emdin M, Lombardi M. Silent myocardial damage in cocaine addicts. Heart. 2011 Dec;97(24):2056-62. doi: 10.1136/hrt.2011.226977. Epub 2011 Jun 20. Erratum In: Heart. 2011 Dec;97(24):2061. — View Citation

DeFilippis EM, Singh A, Divakaran S, Gupta A, Collins BL, Biery D, Qamar A, Fatima A, Ramsis M, Pipilas D, Rajabi R, Eng M, Hainer J, Klein J, Januzzi JL, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Cocaine and Marijuana Use Among Young Adults With Myoc — View Citation

Gatto L, Frati G, Biondi-Zoccai G, Versaci F. Cocaine and acute coronary syndromes: Novel management insights for this clinical conundrum. Int J Cardiol. 2018 Jun 1;260:16-17. doi: 10.1016/j.ijcard.2018.03.011. No abstract available. — View Citation

Kim ST, Park T. Acute and Chronic Effects of Cocaine on Cardiovascular Health. Int J Mol Sci. 2019 Jan 29;20(3):584. doi: 10.3390/ijms20030584. — View Citation

Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001 Aug 2;345(5):351-8. doi: 10.1056/NEJM200108023450507. No abstract available. Erratum In: N Engl J Med 2001 Nov 8;345(19):1432. — View Citation

Ma I, Genet T, Clementy N, Bisson A, Herbert J, Semaan C, Bouteau J, Angoulvant D, Ivanes F, Fauchier L. Outcomes in patients with acute myocardial infarction and history of illicit drug use: a French nationwide analysis. Eur Heart J Acute Cardiovasc Care — View Citation

Rezkalla SH, Kloner RA. Cocaine-induced acute myocardial infarction. Clin Med Res. 2007 Oct;5(3):172-6. doi: 10.3121/cmr.2007.759. — View Citation

US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Curry SJ, Donahue K, Doubeni CA, Epling JW Jr, Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Unhealthy Drug Us — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Complexity and extent of coronary heart disease The Syntax Score (Synergy Between PCI With Taxus and Cardiac Surgery) will be quantified in patients with and without a history of cocaine use. A higher Syntax Score indicates a more complex coronary disease as well as worse prognosis. Score values of 0 to 22 are considered low complexity, 23 to 32 moderate complexity and >32 high complexity. During coronary angiography
Primary Clinical presentation as STEAMI, or NSTEAMI or unstable angina Differences between groups in clinical presentation as STEAMI, NSTEAMI or unstable angina will be based on the findings of the first electrocardiogram registred during admision, following the Fourth Universal Definition of Myocardial Infarction. Up to 24 hours of admission
Primary Mortality Total mortality During hospitalization (up to 30 days)
Primary Severe complications A combined ouctome including: resuscitated cardiac arrest, complex arrhythmia requiring electrical cardioversion, use of inotropes, or mechanical ventilatory support. During hospitalization (up to 30 days)
Secondary Extent of atherosclerotic vascular disease The extent of extracoronary atherosclerotic vascular disease will be quantified by vascular Doppler of the carotids and lower limbs During hospitalization (up to 30 days)
Secondary Myocardial damage The extent of ischemic and non-ischemic myocardial damage will be quantified by cardiac MRI. During hospitalization (up to 30 days)
Secondary Socioeconomic factors: unemployment Unemployment (as a proportion) will be compared between patients with and without a history of cocaine use. During hospitalization (up to 30 days)
Secondary Socioeconomic factors: health insurance Health insurance ownership (as a proportion) will be compared between patients with and without a history of cocaine use. During hospitalization (up to 30 days)
Secondary Socioeconomic factors: highest level of formal education The highest level of formal education (as an ordinal variable from kindergarten = 1 to college = 8) will be compared between patients with and without a history of cocaine use. During hospitalization (up to 30 days)
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Completed NCT04507529 - Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients N/A
Recruiting NCT06066970 - Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
Recruiting NCT03620266 - Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI N/A
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT03668587 - Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Recruiting NCT05371470 - Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation N/A
Recruiting NCT04562272 - Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT06007950 - Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health N/A
Withdrawn NCT05327855 - Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) Phase 2
Recruiting NCT02876952 - High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients N/A
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02711631 - Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation N/A
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A
Completed NCT02305602 - A Study of VentriGel in Post-MI Patients Phase 1